Dry eye disease (DED) is a condition characterized by the loss of tear film homeostasis, caused by the inadequate production or the rapid evaporation of tears. For 13 years, AbbVie’s Restasis was…
Clarivate Epidemiology’s coverage of dry eye disease (DED) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France,…
For more than a decade, AbbVie’s Restasis was the only FDA-approved therapy for dry eye disease (DED) until the launch of Novartis’s Xiidra in 2016, followed by Restasis MultiDose, Sun…
Epidemiology Data Slicer
Dry eye disease (DED) is a chronic, inflammatory, and highly heterogeneous condition of the eye; it is also referred to as dry eye syndrome or keratoconjunctivitis sicca. Although DED represents a…
DED is one of the most common ocular conditions in the United States and Europe. Inflammation plays a prominent role in the pathogenesis of DED, and the condition may eventually lead to damage to…